SARDESSAI, M. S.;BRANDER, M. J.;MIDHA, K. K.;HAWES, E. M., J. LABELLED COMPOUNDS AND RADIOPHARM., 1986, 13, N 3, 317-327
作者:SARDESSAI, M. S.、BRANDER, M. J.、MIDHA, K. K.、HAWES, E. M.
DOI:——
日期:——
[EN] PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES<br/>[FR] COMPOSÉS DE PHÉNOTHIAZINE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER ET D'AUTRES MALADIES NEUROLOGIQUES ET LIÉES À L'ÂGE
申请人:ICAHN SCHOOL MED MOUNT SINAI
公开号:WO2022104070A3
公开(公告)日:2022-06-23
[FR] COMPOSÉS DE PHÉNOTHIAZINE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER ET D'AUTRES MALADIES NEUROLOGIQUES ET LIÉES À L'ÂGE<br/>[EN] PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES
申请人:[en]ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
公开号:WO2022104070A2
公开(公告)日:2022-05-19
Disclosed are phenothiazine compounds which reduce Abeta toxicityin vivo, reduce microglial inflammation as indicated by secretion of TNF-alpha, reduce intracerebral hemorrhagein vivotoxicity as indicated by preserved motor and cognitive function, and SARS-CoV-2 replication. Also disclosed are methods of use thereof for the treatment of disease in a subject in need thereof.